Dose-finding study of KP-607 in patients with onychomycosis (PhaseII)
Latest Information Update: 20 Jan 2022
Price :
$35 *
At a glance
- Drugs KP-607 (Primary)
- Indications Onychomycosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kaken Pharmaceutical
- 18 Jan 2022 Status changed from active, no longer recruiting to completed.
- 29 Dec 2021 New trial record